These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 12405014

  • 1. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
    Gensini GF, Lippi D, Conti AA.
    Recenti Prog Med; 2002 Oct; 93(10):544-53. PubMed ID: 12405014
    [Abstract] [Full Text] [Related]

  • 2. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.
    Hanif K, Bid HK, Konwar R.
    Hypertens Res; 2010 Jan; 33(1):11-21. PubMed ID: 19911001
    [Abstract] [Full Text] [Related]

  • 5. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 6. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB, Coffman TM.
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. Role of the renin-angiotensin-aldosterone system for control of arterial blood pressure following moderate deficit in total body sodium: balance studies in freely moving dogs.
    Seeliger E, Lunenburg T, Ladwig M, Reinhardt HW.
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):e43-51. PubMed ID: 19930429
    [Abstract] [Full Text] [Related]

  • 9. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 10. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 11. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun 06; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 12. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr 06; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 13. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM.
    Acta Diabetol; 2005 Apr 06; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [Abstract] [Full Text] [Related]

  • 14. [What have we learned from converting enzyme inhibitors on renin-angiotensin system?].
    Waeber B, Nussberger J, Brunner HR.
    Rev Prat; 1992 Dec 15; 42(20):2529-32. PubMed ID: 1338608
    [Abstract] [Full Text] [Related]

  • 15. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 15; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 16. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
    Legrand D, Krzesinski JM, Scheen AJ.
    Rev Med Suisse; 2008 Aug 27; 4(168):1792-7. PubMed ID: 18814762
    [Abstract] [Full Text] [Related]

  • 17. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C, Schoemaker RG, van Gilst WH, Roks AJ.
    Clin Sci (Lond); 2009 Feb 27; 116(4):301-14. PubMed ID: 19138171
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease.
    Re RN.
    Nat Clin Pract Cardiovasc Med; 2004 Nov 27; 1(1):42-7. PubMed ID: 16265259
    [Abstract] [Full Text] [Related]

  • 19. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
    Hennig L.
    Clin Nephrol; 2003 Jul 27; 60 Suppl 1():S53-8. PubMed ID: 12940534
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U, Deedwania PC.
    Cardiol Clin; 2008 Nov 27; 26(4):507-26. PubMed ID: 18929228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.